Estrogen Receptor alpha Recombinant Monoclonal Antibody (IRS142RB)

UNIPROT #

P03372

PROTEIN NAME

Estrogen Receptor alpha

SYNONYMS

7*/654 isoform antibody;7*/819 2 isoform antibody;7*/822 isoform antibody;8*/901 isoform antibody;8*/941 isoform antibody;DKFZp686N23123 antibody;ER alpha antibody;ER antibody;ER-alpha antibody;Era antibody;ESR antibody;ESR1 antibody;ESR1_HUMAN antibody;ESRA antibody;Estradiol receptor antibody;Estrogen nuclear receptor alpha antibody;Estrogen receptor 1 antibody;Estrogen receptor alpha 3*,4,5,6,7*/822 isoform antibody;Estrogen receptor alpha antibody;Estrogen receptor alpha delta 3*,4,5,6,7*,8*/941 isoform antibody;Estrogen receptor alpha delta 3*,4,5,6,7*/819 2 isoform antibody;Estrogen receptor alpha delta 4 +49 isoform antibody;Estrogen receptor alpha delta 4*,5,6,7*/654 isoform antibody;Estrogen receptor alpha delta 4*,5,6,7,8*/901 isoform antibody;Estrogen receptor alpha E1 E2 1 2 antibody;Estrogen receptor alpha E1 N2 E2 1 2 antibody;Estrogen receptor antibody;ESTRR antibody;NR3A1 antibody;Nuclear receptor subfamily 3 group A member 1 antibody

SUBCELLULAR LOCATION

Cell membrane, Nucleus, Cytoplasm.

FUNCTION

Estrogen receptor (ER) belongs to the steroid receptor superfamily of nuclear receptors. It is a protein with 553 amino acids. ER mediates regulatory functions of female sex steroids, mainly 17 (E2), on growth, differentiation and function in several target tissues, including female and male reproductive tract, mammary gland, and skeletal and cardiovascular systems. In normal and malignant human breast tissue ER is expressed in stromal cells in addition to epithelia. Only limited data are available on the role of ER in normal and neoplastic tissues. ER is mainly expressed in tumours of female sex steroid hormone responsive tissues such as the mammary gland, endometrium, and ovary. ER protein is expressed in 60-70% of female breast cancers (ER+/PR- 19-22%; ER+/PR+ 49-53%). Other tumours expressing ER are meningiomas, salivary gland tumours, some neuroendocrine tumours, and some colorectal and hepatocellular carcinomas. Uterine cervix and tonsil can be recommended as positive tissue controls for ER. In uterine cervix, virtually all squamous and columnar epithelial cells must show a moderate to strong and distinct nuclear staining reaction. Lymphocytes and endothelial cells must be negative. Tonsil is especially found recommendable as a tool to monitor the level of analytical sensitivity for the demonstration of ER. Dispersed follicular dendritic cells in germinal centers and squamous epithelial cells must show an at least weak but distinct nuclear staining reaction. In addition, tonsil can be used as negative tissue control, as B-cells in mantle zones and within germinal centers must be negative. To validate the specificity of the IHC protocol further, an ER negative breast carcinoma must be included as primary negative tissue control, in which only remnants of normal epithelial and stromal cells should be ER positive, serving as internal positive tissue control. Positive staining reaction of the stromal cells in breast tissue indicates that the IHC protocol provides a high analytical sensitivity for ER, whereas the analytical sensitivity cannot reliably be evaluated in normal epithelial cells in breast as they typically express moderate to high levels of ER.